New drug combo aims to shrink throat tumors before surgery
NCT ID NCT07538206
First seen Apr 25, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This study tests whether giving two drugs (vibecortamab and putilimab) before surgery can shrink tumors in people with advanced laryngeal cancer. The goal is to improve surgical outcomes and possibly preserve the voice box. Ten adults aged 18-80 with resectable, locally advanced laryngeal cancer will receive the drug combination and then undergo standard surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.